The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Myasthenia gravis - Myasthenic-like syndrome
Publications
Pembrolizumab-induced myasthenia gravis: A fatal case report.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2018 Mar;24;146-149 — 2018 Mar — 146-149
Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
Muscle & nerve 2016 06;54;157-61 — 2016 06 — 157-61